Peer-reviewed research
An overview of the published evidence that informs Oprimaze's two-phase design. Every section links to its source studies — and we draw a clear line between what's well established and where research is still maturing.
Appetite regulation
Hunger-driving hormones rise after weight loss and remain elevated for at least a year — pulling the body back toward its previous weight. Structured appetite support during and after loss is one of the few interventions shown to blunt that response.
Metabolic stability
Resting metabolic rate drops after sustained weight loss and stays suppressed, meaning the same intake yields weight gain. Maintenance protocols that target metabolic stability outperform diet-only approaches.
Post-injectable transition
Roughly two-thirds of weight lost on injectable therapy returns within 12 months of stopping in controlled trial settings — most of it in the first six months. A structured maintenance phase is the missing piece in most weight programs.
The appetite active
Oprimaze's active is a hemp-derived blend of THCV, CBD and CBC. THCV is non-intoxicating and acts as a CB1 antagonist — the mirror image of THC, nudging appetite down rather than up. Across preclinical studies it consistently reduces food intake and supports energy expenditure; a human RCT found clear metabolic and glucose-control benefits. We're honest about the maturity here: the mechanism and animal data are strong, human appetite data is still emerging, and we ran our own 100-person consumer study on the formula rather than resting on the literature alone. It is a support tool, not a weight-loss drug.
Compliance & safety
The active is THCV — a distinct hemp-derived cannabinoid, not THC — so the blend contains no THC. Hemp is federally legal under the 2018 Farm Bill at up to 0.3% delta-9 THC; Oprimaze contains none, so it's fully compliant. It's non-intoxicating: it will not get you high. Every batch is third-party lab tested, and because there's no THC the formula is made to be non-detectable on standard workplace drug screens. A certificate of analysis is available per batch on request.
Nasal delivery
These cannabinoids are oil-loving and barely dissolve in water, so swallowed, most of a dose is lost to first-pass metabolism — oral bioavailability runs only ~6–19%. Oprimaze carries each active in a protein-stabilized liposome and delivers it nasally, straight past the liver: published pharmacokinetics put intranasal bioavailability for hemp-derived cannabinoids far higher, roughly 34–46%, which is why a low, gentle dose can still do the job. (The 34–46% figure is delivery-science context from cannabidiol research, not an Oprimaze-specific measurement.)
Every figure on this site is sourced from peer-reviewed published research.